ATAI Investor Presentation Deck
atai Life Sciences: healing mental health disorders so that everyone
everywhere can live a more fulfilled life
1
2
3
4
5
Mental health disorders have become one of largest global health burdens. Depression rates of US
adults saw a ~3x increase since the onset of the COVID-19 pandemic¹
As a response to the technical risks associated with CNS drug development, atai focuses on compound
classes with prior evidence in humans and utilizes a decentralized drug development process
12 active programs: 8 drug and discovery programs and 4 enabling technologies, focusing on
differentiated, potentially disease-modifying therapies
Validation of atai's operating model: IPO of COMPASS Pathways and validating license deal between
Otsuka & Perception
We have a strong cash position of approx. $312M (as of June 30th, 2022) and access to up to $175m
from term loan facility with Hercules, giving cash runway into 2025
03.
(1) THE COVID STATES PROJECT report (May 21, 2021)View entire presentation